Comparison of host response mechanisms evoked by extended spectrum beta lactamase (ESBL)- and non-ESBL-producing uropathogenic E. coli

BMC Microbiology

Katarina Persson²  Bo Söderquist¹  Anna Önnberg¹  Annica Kinnunen²  Isak Demirel² 

[1] Department of Laboratory Medicine, Clinical Microbiology, Örebro University Hospital, Örebro, Sweden;Faculty of Medicine and Health, Örebro University, Örebro, Sweden

关键词: Uropathogenic E. coli;    Polymorphonucleated leukocytes;    Renal epithelial cells;    Urinary tract infections;    Extended spectrum beta-lactamases;   

Others  :  1143348
DOI  :  10.1186/1471-2180-13-181

 received in 2013-01-14, accepted in 2013-07-31,  发布年份 2013

【 摘 要 】

Background

Infections caused by extended spectrum beta-lactamases (ESBL)-producing bacteria have been emerging worldwide and the majority of ESBL-producing E. coli strains are isolated from patients with urinary tracts infections. The purpose of this study was to compare the host-response mechanisms in human polymorphonucleated leukocytes (PMN) and renal epithelial cells when stimulated by ESBL- or non-ESBL-producing uropathogenic E. coli (UPEC) isolates. The host-pathogen interaction of these ESBL-producing strains in the urinary tract is not well studied.

Results

The ability of ESBL strains to evoke ROS-production from PMN cells was significantly higher than that of the non-ESBL strains. The growth of ESBL strains was slightly suppressed in the presence of PMN compared to non-ESBL strains after 30 min and 2 h, but the opposite was observed after 5 and 6 h. The number of migrating PMN was significantly higher in response to ESBL strains compared to non-ESBL strains. Stimulation of A498 cells with ESBL strains elicited lower production of IL-6 and IL-8 compared to non-ESBL strains.

Conclusion

Significant differences in host-response mechanisms were identified when host cells were stimulated by ESBL- or non-ESBL producing strains. The obtained results on the early interactions of ESBL-producing strains with the host immune system may provide valuable information for management of these infections.

【 授权许可】

   
2013 Demirel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 4.

【 参考文献 】

• [1]Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8(3):159-166.
• [2]Pitout JD, Nordmann P, Laupland KB, Poirel L: Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005, 56(1):52-59.
• [3]Khanfar HS, Bindayna KM, Senok AC, Botta GA: Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J Infect Dev Ctries 2009, 3(4):295-299.
• [4]Falagas ME, Karageorgopoulos DE: Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009, 73(4):345-354.
• [5]Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, Hawser S: Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis 2012, 74(1):62-67.
• [6]Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP: Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008, 62(2):284-288.
• [7]Ragnarsdottir B, Fischer H, Godaly G, Gronberg-Hernandez J, Gustafsson M, Karpman D, Lundstedt AC, Lutay N, Ramisch S, Svensson ML, et al.: TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 2008, 38(Suppl 2):12-20.
• [8]Lavigne JP, Blanc-Potard AB, Bourg G, Moreau J, Chanal C, Bouziges N, O'Callaghan D, Sotto A: Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases. Clin Microbiol Infect 2006, 12(12):1199-1206.
• [9]Sahly H, Aucken H, Benedi VJ, Forestier C, Fussing V, Hansen DS, Ofek I, Podschun R, Sirot D, Sandvang D, et al.: Impairment of respiratory burst in polymorphonuclear leukocytes by extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2004, 23(1):20-26.
• [10]Sahly H, Navon-Venezia S, Roesler L, Hay A, Carmeli Y, Podschun R, Hennequin C, Forestier C, Ofek I: Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae. Antimicrob Agents Chemother 2008, 52(9):3029-3034.
• [11]Sahly H, Aucken H, Benedi VJ, Forestier C, Fussing V, Hansen DS, Ofek I, Podschun R, Sirot D, Tomas JM, et al.: Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2004, 48(9):3477-3482.
• [12]Bristianou M, Panagou C, Adamis T, Raftogiannis M, Antonopoulou A, Chrisofos M, Galani I, Kanellakopoulou K, Tsaganos T, Giamarellos-Bourboulis EJ: The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study. Int J Antimicrob Agents 2008, 31(3):216-223.
• [13]Billips BK, Forrestal SG, Rycyk MT, Johnson JR, Klumpp DJ, Schaeffer AJ: Modulation of host innate immune response in the bladder by uropathogenic Escherichia coli. Infect Immun 2007, 75(11):5353-5360.
• [14]Hunstad DA, Justice SS, Hung CS, Lauer SR, Hultgren SJ: Suppression of bladder epithelial cytokine responses by uropathogenic Escherichia coli. Infect Immun 2005, 73(7):3999-4006.
• [15]Loughman JA, Hunstad DA: Attenuation of human neutrophil migration and function by uropathogenic bacteria. Microbes Infect 2011, 13(6):555-565.
• [16]Onnberg A, Molling P, Zimmermann J, Soderquist B: Molecular and phenotypic characterization of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases with focus on CTX-M in a low-endemic area in Sweden. APMIS 2011, 119(4–5):287-295.
• [17]Doumith M, Day MJ, Hope R, Wain J, Woodford N: Improved multiplex PCR strategy for rapid assignment of the four major Escherichia coli phylogenetic groups. J Clin Microbiol 2012, 50(9):3108-3110.
• [18]Nielubowicz GR, Mobley HL: Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010, 7(8):430-441.
• [19]Vila J, Simon K, Ruiz J, Horcajada JP, Velasco M, Barranco M, Moreno A, Mensa J: Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis 2002, 186(7):1039-1042.
• [20]Wiles TJ, Kulesus RR, Mulvey MA: Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol 2008, 85(1):11-19.
• [21]Hofman P, Le Negrate G, Mograbi B, Hofman V, Brest P, Alliana-Schmid A, Flatau G, Boquet P, Rossi B: Escherichia coli cytotoxic necrotizing factor-1 (CNF-1) increases the adherence to epithelia and the oxidative burst of human polymorphonuclear leukocytes but decreases bacteria phagocytosis. J Leukoc Biol 2000, 68(4):522-528.
• [22]Yadav M, Zhang J, Fischer H, Huang W, Lutay N, Cirl C, Lum J, Miethke T, Svanborg C: Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence. PLoS Pathog 2010, 6(9):e1001120.
• [23]Agace WW, Patarroyo M, Svensson M, Carlemalm E, Svanborg C: Escherichia coli induces transuroepithelial neutrophil migration by an intercellular adhesion molecule-1-dependent mechanism. Infect Immun 1995, 63(10):4054-4062.
• [24]Godaly G, Proudfoot AE, Offord RE, Svanborg C, Agace WW: Role of epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in Escherichia coli-induced transuroepithelial neutrophil migration. Infect Immun 1997, 65(8):3451-3456.
• [25]Hang L, Frendeus B, Godaly G, Svanborg C: Interleukin-8 receptor knockout mice have subepithelial neutrophil entrapment and renal scarring following acute pyelonephritis. J Infect Dis 2000, 182(6):1738-1748.
• [26]Uehling DT, Johnson DB, Hopkins WJ: The urinary tract response to entry of pathogens. World J Urol 1999, 17(6):351-358.
• [27]Klumpp DJ, Weiser AC, Sengupta S, Forrestal SG, Batler RA, Schaeffer AJ: Uropathogenic Escherichia coli potentiates type 1 pilus-induced apoptosis by suppressing NF-kappaB. Infect Immun 2001, 69(11):6689-6695.
• [28]Deschamps C, Clermont O, Hipeaux MC, Arlet G, Denamur E, Branger C: Multiple acquisitions of CTX-M plasmids in the rare D2 genotype of Escherichia coli provide evidence for convergent evolution. Microbiology 2009, 155(Pt 5):1656-1668.
• [29]Rogers BA, Sidjabat HE, Paterson DL: Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011, 66(1):1-14.
• [30]Karfunkel D, Carmeli Y, Chmelnitsky I, Kotlovsky T, Navon-Venezia S: The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel. Eur J Clin Microbiol Infect Dis 2012, 32(4):513-521.
• [31]Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ: The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008, 6(1):17-27.